Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1995; 74(01): 066-070
DOI: 10.1055/s-0038-1642654
DOI: 10.1055/s-0038-1642654
Symposium
Natural Inhibitors of Fibrinolysis
The PAI-1/Vitronectin Interaction: Two Cats in a Bag?
Authors
Further Information
Publication History
Publication Date:
09 July 2018 (online)
-
References
- 1 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 190: 381-387
- 2 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Hemostasis and Thrombosis. Coller B. ed. Vol 9 W.B.Saunders; Philadelphia, PA: 1989: 87-115
- 3 Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovascular Med 1991; 1: 99-102
- 4 Dano K, Andreasen P, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
- 5 Vassalh J-D, Sappino A-P, Berlin D. The plasminogen activator/plasmin system. J din Invest 1991; 88: 1067-1072
- 6 Carrell R, Travis J. a1-Antitrypsin and the serpins: variation and countervariation. TIBS 1985; 20-24
- 7 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen ativators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
- 8 Declerck PJ, De Mol M, Alessi M-C, Baudner S, Paques E-P, Preissner KT, Muller-Berghaus G, Collen D. Purfication and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454-15461
- 9 Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988; 242: 125-128
- 10 Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. J Biol Chem 1989; 264: 936-939
- 11 Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Muller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490-18498
- 12 Seiffert D, Wagner NN, Loskutoff DJ. Seru-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol 1990; 111: 1283-1291
- 13 Seiffert D, Loskutoff DJ. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 1991; 266: 2824-2830
- 14 Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987; 70: 721-728
- 15 Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT. Mapping of binding sites forheparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin’s heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin foimation. J Biol Chem 1992; 267: 12098-12105
- 16 Mimuro J, Muramatsu S, Kurano Y, Uchida Y, Ikadai H, Watanabe S, Sakata Y. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistiy 1993; 32: 2314-2320
- 17 Tomasini BR, Mosher DF. Vitronectin. In: Progress in Hemostasis and Thrombosis. Coller B. ed. Vol (10) W.B.Saunders; Philadelphia, PA: 1990. 10. 269-305
- 18 Sigurdardottir O, Wiman B. Identification of a PAI-1 binding site in vitronectin. Biochim Biophys Acta 1994; 1208: 104-110
- 19 Lawrence DA, Beikenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-15228
- 20 Ciambrone G, Loskutoff DJ. unpublished observations
- 21 van Meijer M, Gebbink RK, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Lett 1994; 352: 342-346
- 22 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273
- 23 Ehrlich HJ, Gebbink RK, Keijer J, Pannekoek H. Elucidation of structural requirements of plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem 1992; 267: 11606-11611
- 24 Nakashima N, Miyazaki K, Ishikawa M, Yatohgo T, Ogawa H, Uchibori H, Matsumoto I, Seno N, Hayashi M. Vitronectin diversity in evolution but uniformity in ligand binding and size of the core polypeptide. Biochim Biophys Acta 1992; 1120: 1-10
- 25 Fiyklund L, Uthne K, Sievertsson H. Isolation and characterization of polypeptides from human plasma enhancing the growth of human normal cells in culture. Biochem Biophys Res Comm 1974; 61: 950-956
- 26 Heldin C-H, Fryklund L. Somatomedin B: Mitogenic activity derived from contaminant epidermal growth factor. Science 1981; 213: 1121-1123
- 27 Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4: 2519-2524
- 28 Salonen E-M, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M, Dano K, Gailit J, Ruoslahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989; 264: 6339-6343
- 29 Sigurdardottir O, Wiman B. Studies on the interaction between plasminogen inhibitor-1 and vitronectin. Fibrinolysis 1992; 6: 27-32
- 30 Seiffert D, Loskutoff DJ. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terimal fragment of bovine vitronectin. Biochim Biophys Acta 1991; 1078: 23-30
- 31 Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin. J Biol Chem 1994 269: 2659-2666
- 32 Tomassini-Johansson BR, Ruoslahti E, Pierschbacher MD. A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin. Matrix 1993; 13: 203-214
- 33 Gechtman Z, Shaima R, Kreizman T, Fridkin M, Shaltiel S. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. FEBS Lett 1993; 315: 293-297
- 34 Wagner O, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest 1989; 84: 647-655
- 35 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastractural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299
- 36 Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissociation. J Biol Chem 1992; 267: 17128-17135
- 37 Lambers JW J, Cammenga M, Konig B, Pannekoek H, van Mourik JA. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987; 262: 17492-17496
- 38 Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations cm its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
- 39 Decleik PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
- 40 Woolf N. Thrombosis and atherosclerosis. In: Heamostasis and Thrombosis. Bloom AL, Thomas DP. eds Churchill Livingstone; Edinburgh: 1981: 527-553
- 41 Levi M, Biemond BJ, Van Zooneveld AJ, Woulter ten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305
- 42 Potter van Loon BJ, Rijken DC, Broomer EJ P, Van der Maas AP C. The amount of plasminogen, tissue type plasminogen activatorand plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992; 67: 101
- 43 Merberg DM, Fitz U, Temple P, Giannotti J, Murtha P, Fitzgerald M, Scaltreto J, Kelleher K, Preissner K, Kriz R, Jacobs K, Turner K. A comparison of vitronectin and megakaryocyte stimulating factor. In: Biology of Vitronectins and their Receptors. Rosenblatt S, Preissner KR, Kost C, Wegerhoff J, Mosher DF. eds. Elsevier Science Publishers B.V.; The Netherlands: 1993: 45-55
- 44 Grundmann U, Romisch J, Siebold B, Bohn H, Amann E. Cloning and expression of a cDNA encoding human placental protein 11, a putative serine protease with diagnostic significance as a tumor marker. DNA Cell Biol 1990; 9: 243-250
- 45 Baughman G, Lesley J, Trotter J, Hyman R, Bourgeois S. Tcl-30, a new T cell-specific gene expressed in immature glucocorticoid-sensitive thymocytes. J Immunol 1992; 149: 1488-1496
- 46 Buckley MF, Loveland KA, McKinstry WJ, Garson OM, Goding JW. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem 1990; 265: 17506-17511
- 47 Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991; 88: 9402-9406